DexCom, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 2.45B | 2.91B | 3.62B | 4.03B | 4.66B | 15.6% | |
| Cost of Revenue | (768.00M) | (1.03B) | (1.33B) | (1.59B) | (1.86B) | 16.6% | |
Gross Profit | 1.68B | 1.88B | 2.29B | 2.44B | 2.80B | 14.9% | |
| Operating Expenses | |||||||
| Research & Development | (604.20M) | (484.20M) | (505.80M) | (552.40M) | (599.10M) | 8.5% | |
| Selling, General & Administrative | (810.50M) | (1.01B) | (1.19B) | (1.29B) | (1.29B) | 0.4% | |
| Depreciation & Amortization | (101.90M) | (155.90M) | (186.00M) | (217.70M) | (251.80M) | 15.7% | |
Operating Income (EBIT) | 265.80M | 391.20M | 597.70M | 600.00M | 911.80M | 52.0% | |
| Non-Operating Items | |||||||
| Interest Income | 1.70M | 23.80M | 135.00M | 134.20M | 112.70M | -16.0% | |
| Interest Expense | (18.80M) | (18.60M) | (20.30M) | (19.00M) | (18.30M) | -3.7% | |
| Other Income/Expenses (Net) | -9.00M | -400.00K | 112.70M | 109.00M | 176.60M | 62.0% | |
Income Before Tax | 256.80M | 390.80M | 710.40M | 709.00M | 1.09B | 53.5% | |
| Income Tax Expense | (39.90M) | (49.60M) | (168.90M) | (132.80M) | (252.10M) | 89.8% | |
Net Income | 216.90M | 341.20M | 541.50M | 576.20M | 836.30M | 45.1% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $1 | $1 | $1 | $1 | $2 | 46.6% | |
| Weighted Avg Shares Outstanding | 386.90M | 389.40M | 386.00M | 404.63M | 390.20M | -3.6% | |
| Weighted Avg Shares Outstanding (Diluted) | 428.80M | 427.50M | 425.50M | 412.70M | 405.50M | -1.7% | |
EBITDA | 377.50M | 565.30M | 916.70M | 945.70M | 1.36B | 43.7% |
Explore DXCM
DXCM in the Healthcare
Large Cap